Mori, S.; Tsuemoto, N.; Kawachi, E.; Takubo, C.; Tanatani, A.; Kagechika, H.. Development of retinoic acid receptor antagonists bearing trans-SF4-alkynyl structure as a linear linker. Tetrahedron . 2022.08; 123 132967. ( DOI )

Hara, Y.; Ando, F.; Oikawa, D.; Ichimura, K.; Yanagawa, H.; Sakamaki, Y.; Nanamatsu, A.; Fujiki, T.; Mori, S.; Suzuki, S.; Yui, N.; Mandai, S.; Susa, K.; Mori, T.; Sohara, E.; Rai, T.; Takahashi, M.; Sasaki, S.; Kagechika, H.; Tokunaga, F.; Uchida, S.. LRBA is essential for urinary concentration and body water homeostasis Proc. Natl. Acad. Sci. USA. 2022.07; 119 (30): e2202125119.

Oikawa, T.; Fujii, S.; Mori, S.; Masuno, H.; Kawachi, E.; Kagechika, H. . Structural Development of Silicon-Containing Retinoids: Structure–Activity Relationship Study of the Hydrophobic Pharmacophore of Retinobenzoic Acids Using Silyl Functionalities ChemMedChem. 2022.06; e202200176.

Yoshihara, A.; Kawasaki, H.; Masuno, M.; Takada, K.; Numoto, N.; Ito, N.; Hirata, N.; Kanda, Y.; Ishizawa, M.; Makishima, M.; Kagechika, H.; Tanatani, A.. Lithocholic Acid Amides as Potent Vitamin D Receptor Agonists Biomolecules. 2022.01; 12 (1): 130.

Takayanagi, S.; Watanabe, K.; Maruyama, T.; Ogawa, M.; Morishita, K.; Soga, M.; Hatta, T.; Natsume, T.; Hirano, T.; Kagechika, H.; Hattori, K.; Naguro, I.; Ichijo, H.. ASKA technology-based pull-down method reveals a suppressive effect of ASK1 on the inflammatory NOD-RIPK2 pathway in brown adipocytes Sci. Rep.. 2021.10; 11 22009.

Fujii, S.; Kikuchi, E.; Suzuyama, H.; Watanabe, Y.; Ishigami-Yuasa, M.; Masuno, H.; Mori, T.; Isobe, K.; Uchida, S.; Kagechika, H.. Structural Development of Salicylanilide-Based SPAK Inhibitors as Candidate Antihypertensive Agents ChemMedChem. 2021.09; 16 (18): 2817-2822.

Liu, L.; Koike, H.; Ono, T.; Hayashi, S.; Kudo, F.; Kaneda, A.; Kagechika, H.; Manabe, I.; Nakashima, T.; Oishi. Y.. Identification of a KLF5-dependent program and drug development for skeletal muscle atrophy Proc Natl Acad Sci., USA. 2021.08; 118 (35): e2102895118. ( PubMed, DOI )

Konishi, M.; Noguchi, S.; Inoue, T.; Inoue, Y. U.; Nishino, I.; Mori, S.; Iinuma, H.; Manaka, N.; Kagechika, H.; Uryash, A.; Adams, J.; Lopez, J. R.; Liu, X. C.; Diggle, C.; Allen, P. D.; Kakizawa, S.; Ikeda, K.; Lin, B. Z.; Ikemi, Y.; Nunomura, K.; Nakagawa, S.; Sakurai, T.; Murayama, T.. A novel RyR1-selective inhibitor prevents and rescues sudden death in mouse models of malignant hyperthermia and heat stroke Nature Commun.. 2021.07; 12 (1): 4293. ( DOI )

Fujii, S.; Kikuchi, E.; Suzuyama, H.; Watanabe, Y.; Ishigami-Yuasa, M.; Masuno, H.; Mori, T.; Isobe, K.; Uchida, S.; Kagechika, H.. Structural Development of Salicylanilide-Based SPAK Inhibitors as Candidate Antihypertensive Agents ChemMedChem . 2021.07; 16 (18): 2817-2822. ( PubMed, DOI )

Lin, Y.-W.; Nhieu, J.; Wei, C.-W.; Lin, Y.-L.; Kagechika, H.; Wei, L.-N.. Regulation of exosome secretion by cellular retinoic acid binding protein 1 contributes to systemic anti-inflammation Cell Commun. Signal.. 2021.06; 19 (1): 69. ( PubMed, DOI )

Osada, H.; Nawa, M.; Nakahama, K.; Ishigami-Yuasa, M.; Kagechika, H.; Sugimura, H.; Iwasa, H.; Arimoto-Matsuzaki, K.; Nishina, H.; Hata, Y.. CSE1L promotes nuclear accumulation of transcriptional coactivator TAZ and enhances invasiveness of human cancer cells J. Biol. Chem.. 2021.05; 297 (1): 100803. ( PubMed, DOI )

Kato, D.; Shiraishi, T.; Kagechika, H.; Hirano, T.. Design, synthesis and antitumor activity of phthalazine-1,4-dione-based menaquinone analogs Bioorg. Med. Chem. Lett.. 2021.04; 43 128065. ( PubMed, DOI )

Kato Daiki, Shiraishi Takuya, Kagechika Hiroyuki, Hirano Tomoya. 6-Arylcoumarin as a Scaffold of Photofunctional Molecules with OFF-ON-OFF Type Regulation JOURNAL OF ORGANIC CHEMISTRY. 2021.02; 86 (3): 2264-2270. ( PubMed, DOI )

Cione, E.; Caroleo, M. C.; Kagechika, H.; Manetti, F.. Pharmacophore-guided repurposing of fibrates and retinoids as GPR40 allosteric ligands. J. Enzyme Inhibit. Med. Chem. 2021.02; 36 (1): 377-383. ( PubMed, DOI )

Sakakitani, S.; Podyma-Inoue, K. A. ; Takayama, R.; Takahashi, K .; Ishigami-Yuasa, M.; Kagechika, H.; Harada, H.; Watabe, T.. Activation of beta 2-adrenergic receptor signals suppresses mesenchymal phenotypes of oral squamous cell carcinoma cells Cancer Sci.. 2021; 112 (1): 155-167. ( DOI )

Fujii, S.; Sekine, R.; Kano, A.; Masuno, H.; Kawachi, E.; Hirano, T.; Kagechika, H.. Synthesis and Structure-Activity Relationship Study of 1,12-Dicarba-closo-dodecaborane-based Triol Derivatives as Nonsecosteroidal Vitamin D Analogs Heterocycles. 2021; 103 (1): 444-458. ( DOI )

Arimura, M.; Tanaka, K.; Kanda, M.; Urushibara, K.; Fujii, S.*; Katagiri, K.; Azumaya, I.; Kagechika, H.; Tanatani, A.. Construction of Aromatic Multilayered Structures Based on the Conformational Properties of N,N’-Dimethylated Squaramide ChemPlusChem. 2021; 86 (1): 198-205. ( PubMed, DOI )

Sasaki, H.; Masuno, H.; Kawasaki, H.; Yoshihara, A.; Numoto, N.; Ito, N.; Ishida, H.; Yamamoto, K.; Hirata, N.; Kanda, Y.; Kawachi, E.; Kagechika, H.; Tanatani, A.. Lithocholic Acid Derivatives as Potent Vitamin D Receptor Agonists J. Med. Chem.. 2021; 64 (1): 516-526. ( PubMed, DOI )

Urushibara, K.; Yamada, T.; Yokoyama, A.; Mori, H.; Masu, H.; Azumaya, I.; Kagechika, H.; Yokozawa, T.; Tanatani, A.. Development of Helical Aromatic Amide Foldamers with a Diphenylacetylene Backbone J. Org. Chem.. 2020; 85 (4): 2019-2039. ( PubMed, DOI )

Sato, A.; Shimizu, M.; Goto, T.; Masuno, H.; Kagechika, H.; Tanaka, N. ; Shibuya, H.. WNK regulates Wnt signalling and beta-Catenin levels by interfering with the interaction between -Catenin and GID Communications Biol.. 2020; 3 (1): 666. ( PubMed, DOI )

Fujii, S.; Kikuchi, E.; Watanabe, Y.; Suzuyama, H.; Ishigami-Yuasa, M.; Mori, T.; Isobe, K.; Uchida, U.; Kagechika, H.. Structural development of N-(4-phenoxyphenyl)benzamide derivatives as novel SPAK inhibitors blocking WNK kinase signaling Bioorg. Med. Chem. Lett. . 2020; 30 (17): 127408. ( PubMed, DOI )

Koga, H.; Negishi, M.; Kinoshita, M.; Fujii, S.; Mori, S.; Ishigami-Yuasa, M.; Kawachi, E.; Kagechika, H.; Tanatani, A.. Development of Androgen-Antagonistic Coumarinamides with a Unique Aromatic Folded Pharmacophore Int. J. Mol. Sci.. 2020; 21 (15): 5584. ( PubMed, DOI )

Kodaka, M.; Arimoto-Matsuzaki, K.; Kitamura, M.; Xu, X.; Yang, Z.; Nakagawa, K.; Maruyama, J.; Ishii, K.; Akazawa, C.; Oyaizu, T.; Yamamoto, N.; Enomoto, M.; Ishigami-Yuasa, M.; Tsuemoto, N.; Ito, S.; Kagechika, H.; Nishina, H.; Hata, Y.. Characterization of a novel compound that promotes myogenesis via Akt and transcriptional co-activator with PDZ-binding motif (TAZ) in mouse C2C12 cells Plos ONE. 2020; 15 (4): e0231265. ( PubMed, DOI )

Ishihara, E.; Nagaoka, Y.; Okuno, T.; Kofuji, S.; Ishigami-Yuasa, M.; Kagechika, H.; Kamimura, K.; Terai, S.; Yokomizo, T.; Sugimoto, Y.; Fujita, Y.; Suzuki, A.; Nishina, H.. Prostaglandin E-2 and its receptor EP2 trigger signaling that contributes to YAP-mediated cell competition Genes to Cells. 2020; 25 (3): 197-214. ( PubMed, DOI )

Park SW, Nhieu J, Persaud SD, Miller MC, Xia Y, Lin YW, Lin YL, Kagechika H, Mayo KH, Wei LN. Publisher Correction: A new regulatory mechanism for Raf kinase activation, retinoic acid-bound Crabp1. Scientific reports. 2019.11; 9 (1): 17042. ( PubMed, DOI )

Ishigami-Yuasa, M.; Ekimoto, H.; Kagechika, H.. Class IIb HDAC inhibition enhances the inhibitory effect of Am80, a synthetic retinoid, in prostate cancer Biol. Pharm. Bull.. 2019.03; 42 (3): 448-452. ( PubMed, DOI )

McDonald, M. G.; Yeung, C. K.; Teitelbaum, A. M.; Johnson, A. L.; Fujii, S.; Kagechika, H.; A New LC-MS Assay for the Quantitative Analysis of Vitamin K Metabolites in Human Urine Rettie, A. E.. A New LC-MS Assay for the Quantitative Analysis of Vitamin K Metabolites in Human Urine J. Lipid Res.. 2019; 60 (4): 892-899. ( DOI )

Kanda, M.; Urushibara, Ko.; Park, S.; Fujii, S.; Masu, H.; Katagiri, K.; Azumaya, I.; Kagechika, H.; Tanatani, A.. Spontaneous Chiral Resolution of N,N’-Diarylsquaramides : Formation of Various Types of One-handed Helical Networks During Crystallization Tetrahedron . 2019; 75 (19): 2771-2777. ( DOI )

Kaitoh, K.; Nakatsu, A.; Mori, S.; Kagechika, H.; Hashimoto, Y.; Fujii, S.. Design, synthesis and biological evaluation of novel nonsteroidal progesterone receptor antagonists based on phenylamino-1,3,5-tirazine scaffold Chem. Pharm. Bull.. 2019; 67 (6): 566-575. ( PubMed, DOI )

Endo, Y.; Sugiura, Y.; Funasaki, M.; Kagechika, H.; Ishibashi, M.; Ohsaki, A.. Two new alkaloids from Crinum asiaticum var. japonicum. J. Nat. Med.. 2019; 73 (3): 648-652. ( PubMed, DOI )

Fujii, S.; Yanagida, N.; Mori, S.; Kawachi, E.; Kagechika, H. Design and synthesis of cyclohexyl-p-carborane derivatives as a new class of progesterone receptor antagonists Heterocycles . 2019; 99 (1): 425-445. ( DOI )

Park, S. W.; Nhieu, J.; Persaud, S. D.; Miller, M. C.; Xia, Y.; Lin, Y.-W.; Lin, Y.-L.; Kagechika, H.; Mayo, K. H.; Wei, L.-N.. A new regulatory mechanism for Raf kinase activation, retinoic acid-bound Crabp1 Sci. Rep.. 2019; 9 10929. ( DOI )

Mori, S.; Tsuemoto, N.; Kasagawa, T.; Nakano, E.; Fujii, S.; Kagechika, H.. Development of Boron-Cluster-Based Progesterone Receptor Antagonists Bearing a Pentafluorosulfanyl (SF5) Chem. Pharm. Bull.. 2019; 67 (12): 1278-1283.

Yokoo, H.; Kagechika, H.; Ohsaki, A; Hirano T.. A Polarity-Sensitive Fluorescent Amino Acid and its Incorporation into Peptides for the Ratiometric Detection of Biomolecular Interactions ChemPlusChem. 2019; 84 1716-1719. ( DOI )

Mori, S.; Iinuma, H.; Manaka, N.; Ishigami-Yuasa, M.; Murayama, T.; Nishijima, Y.; Sakurai, A.; Arai, R.; Kurebayashi, N.; Sakurai, T.; Kagechika, H.. Structural development of a type-1 ryanodine receptor (RyR1) Ca2+-release channel inhibitor guided by endoplasmic reticulum Ca2+ assay Eur. J. Med. Chem.. 2019; 179 837-848. ( PubMed, DOI )

Masuno, H.; Kazui, Y.; Tanatani, A.; Fujii, S.; Kawachi, E.; Ikura, T.; Ito, N.; Yamamoto, K.; Kagechika, H.. Development of Novel Lithocholic Acid Derivatives as Vitamin D Receptor Agonists Bioorg. Med. Chem. 2019; 27 (16): 3674-3681. ( PubMed, DOI )

Mori S, Tsuemoto N, Kasagawa T, Nakano E, Fujii S, Kagechika H. Development of Boron-Cluster-Based Progesterone Receptor Antagonists Bearing a Pentafluorosulfanyl (SF₅) Group. Chemical & pharmaceutical bulletin. 2019; 67 (12): 1278-1283. ( PubMed, DOI )

Urushibara, K.; Masu, H.; Mori, H.; Azumaya, I.; Hirano, T.; Kagechika,H.; Tanatani, A. . Synthesis and Conformational Analysis of Alternately N-Alkylated Aromatic Amide Oligomers J. Org. Chem.. 2018.11; 83 (23): 14338-14349. ( PubMed, DOI )

Kazui, Y.; Fujii, S.; Yamada, A.; Ishigami-Yuasa, M.; Kagechika, H.; Tanatani, A.. Structure-Activity Relationship of Novel Androgen Receptor Antagonists Bearing a (Benzoylaminophenoxy)phenol Pharmacophore. Bioorg. Med. Chem.. 2018.10; 26 (18): 5118-5127. ( PubMed, DOI )

Timalsina, S.; Arimoto-Matsuzaki, K.; Kitamura, M.; Xu, X.; Wenzhe, Q.; Ishigami-Yuasa, M.; Kagechika, H.; Hata, Y.. Chemical compounds that suppress hypoxia-induced stress granule formation enhance cancer drug sensitivity of human cervical cancer HeLa cells. J. Biochem.. 2018.10; 164 (5): 381-391. ( PubMed, DOI )

Li, M.; Qin, X.-Y.; Furutani, Y.; Inoue, I.; Sekihara, S.; Kagechika, H.; Kojima S.. Prevention of acute liver injury by suppressing plasma kallikrein-dependent activation of latent TGF-β Biochem. Biophys. Res. Chem.. 2018.09; 504 (4): 857-864. ( PubMed, DOI )

Loppi, S.; Kolosowska, N.; Kärkkäinen, O.; Korhonen, P.; Huuskonen, M.; Grubman, A.; Dhungana, H.; Wojciechowski, S.; Pomeshchik, Y.; Giordano, M.; Kagechika, H.; White, A.; Auriola, S.; Koistinaho, J.; Landreth, G.; Hanhineva, K.; Kanninen, K.; Malm, T.. HX600, a synthetic agonist for RXR-Nurr1 heterodimer complex, preventsischemia-induced neuronal damag Brain Behav. Immunol.. 2018.09; 73 670-681. ( DOI )

Hirano, T.; Fujiwara, T.; Niwa, H.; Hirano, M.; Ohira, K.; Okazaki, Y.; Sato, S.; Umehara, T.; Maemoto, Y.; Ito, A.; Yoshida, M.; Kagechika, H.. Development of novel inhibitors for histone methyltransferase SET7/9 based on cyproheptadine ChemMedChem. 2018.08; 13 (15): 1530-1540. ( PubMed, DOI )

Fujii, S.; Mori, S.; Kagechika, H.; Parra, M. A. M.; Gronemeyer, H.. Development of biotin-retinoid conjugates as chemical probes for analysis of retinoid function. Bioorg. Med. Chem. Lett.. 2018.07; 28 (14): 2442-2445. ( PubMed, DOI )

Nishiyama, Y.; Mori, S.; Makishima, M.; Fujii, S.; Kagechika, H.; Hashimoto, Y.; Ishikawa, M.. Novel non-steroidal progesterone receptor (PR) antagonists with a phenanthridinone skeleton. ACS Med. Chem. Lett.. 2018.07; 9 (7): 641-645. ( PubMed, DOI )

Qin, X.-Y.; Suzuki, H.; Honda, M.; Okada, H.; Kaneko, S.; Inoue, I.; Ebisui, E.; Hashimoto, K.; Carninci, P.; Kanki, K.; Tatsukawa, H.; Ishibashi, N.; Masaki, T.; Matsuura, T.; Kagechika, H.; Toriguchi, K.; Hatano, E.; Shirakami, Y.; Shiota, G.; Shimizu, M.; Moriwaki, H.; Kojima, S. . Prevention of hepatocellular carcinoma by targeting MYCN-positive liver cancer stem cells with acyclic retinoid. Proc. Nat. Acad. Sci. USA. 2018.06; 115 (19): 4969-4974. ( PubMed, DOI )

Murayama, T.; Kurebayashi, Ishigami-Yuasa, M.; Mori, A.; Suzuki, Y.; Akima, R.; Ogawa, H.; Suzuki, J.; Kanemaru, K.; Oyamada, H.; Kiuchi, Y.; Iino, K.; Kagechika, H.; Sakurai, T. . Efficient High-Throughput Screening by Endoplasmic Reticulum Ca2+ Measurement to Identify Inhibitors of Ryanodine Receptor Ca2+-Release Channels Mol. Pharmacol. . 2018.06; 94 (1): 722-730. ( PubMed, DOI )

Park, S.; Uchida, J.; Urushibara, K.; Kagechika, H.; Kato, T.; Tanatani, A.. Self-assembly of Liquid-crystalline Squaramides. Chem. Lett.. 2018.04; 47 (4): 601-604. ( DOI )

Urushitani, H.; Katsu, Y.; Kagechika, H.; Sousa, A. C. A.; Barroso, C. M.; Ohta, Y.; Shiraishi, H.; Iguchi, T.; Horiguchi, T.. Characterization and comparison of transcriptional activities of the retinoid X receptors by various organotin compounds in three prosobranch gastropods; Thais clavigera, Nucella lapillus and Babylonia japonica. Aquatic Toxicol. . 2018.04; 199 103-115. ( PubMed, DOI )

Ando, F.; Mori, S.; Yui, N.; Morimoto, T.; Nomura, N.; Sohara, E.; Rai, T.; Sasaki, S.; Kondo, Y.; Kagechika, H.; Uchida, S.. AKAPs-PKA disruptors increase AQP2 activity independently of vasopressin in a model of nephrogenic diabetes insipidus Nature Commun. 2018.04; 9 1411. ( DOI )

Shimada, S.; Akiyama, Y.; Mogushi, K.; Ishigami-Yuasa, M.; Kagechika, H.; Nagasaki, H.; Fukamachi, H.; Yuasa, Y.; Tanaka, S.. Identification of selective inhibitors for diffuse-type gastric cancer cells by screening of annotated compounds in preclinical models. Br J Cancer . 2018.04; 118 (7): 972-984. ( PubMed, DOI )

Tojo, Y.; Urushibara, K.; Yamamoto, S.; Mori, H.; Masu, H.; Kudo, M.; Hirano, T.; Azumaya, I.; Kagechika, H.; Tanatani, A.. Conformational Properties of Aromatic Oligoamides Bearing Pyrrole Rings. J. Org. Chem.. 2018.04; 83 (8): 4606-4617. ( PubMed, DOI )

Yokoo, H.; Ohsaki, A.; Kagechika, H.; Hirano, T.. Unique properties of 1,5-naphthyridin-2(1H)-one derivatives as environmental-polarity-sensitive fluorescent dyes. Eur. J. Org. Chem.. 2018.03; 2018 (5): 679-687. ( DOI )

Maruyama, J.; Inami, K.; Michishita, F.; Jiang, X. L.; Iwasa, H.; Nakagawa, K.; Ishigami-Yuasa, M.; Kagechika, H.; Miyamura, N.; Hirayama, J.; Nishina, H.; Nogawa, D.; Yamamoto, K.; Hata, Y.. Novel YAP1 Activator, Identified by Transcription-Based Functional Screen, Limits Multiple Myeloma Growth. Mol. Cancer Res.. 2018.02; 16 (2): 197-211. ( PubMed, DOI )

Mori, S.; Takagaki, R.; Fujii, S.; Urushibara, K.; Tanatani, A.; Kagechika, H.. Novel non-steroidal progesterone receptor ligands based on m-carborane containing a secondary alcohol: effect of chirality on ligand activity Chem. Pharm. Bull.. 2017.11; 65 (11): 1051-1057. ( PubMed, DOI )

Endo,Y.; Kasahara,T.; Harada,K.; Kubo, M.; Etoh, T.; Ishibashi, M.; Ishiyama, A.; Iwatsuki, M.; Otoguro, K.; Ohmura, S.; Akisue, G.; Hirano, T.; Kagechika, H.; Fukuyama, Y.; Ohsaki, A.. Sucupiranins A−L, Furanocassane Diterpenoids from the Seeds of Bowdichia virgilioides. J. Nat. Prod. . 2017.11; 80 (12): 3120-3127. ( PubMed, DOI )

Hoang, H. N.; Granero-Fernandez, E.; Yamada, S.; Mori, S.; Kagechika, H.; Medina-Gonzalez, Y.; Matsuda, T.. Modulating Biocatalytic Activity toward Sterically Bulky Substrates in CO2-Expanded Biobased Liquids by Tuning the Physicochemical Properties. ACS Sus. Chem. Eng.. 2017.10; 5 (11): 11051-11059. ( DOI )

Yamasaki, R.; Iida, M.; Ito, A.; Fukuda, K.; Tanatani, A.; Kagechika, H., Masu, H. Okamoto, I. . Crystal Engineering of N,N’-Diphenylurea Compounds Featuring Phenyl-Perfluorophenyl Interaction Crystal Growth Des.. 2017.09; 17 5858-5866.

Suzuki, D.; Saito-Hakoda, A.; Ito, R.; Shimizu, K.; Parvin, R.; Shimada, H.; Noro, E.; Suzuki, S.; Fujiwara, I.; Kagechika, H.; Rainey, W. E.; Kure, S.; Ito, S.; Yokoyama, A.; Sugawara, A. . Suppressive effects of RXR agonist PA024 on adrenal CYP11B2 expression, aldosterone secretion and blood pressure Plos ONE. 2017.08; 12 (8): e0181055. ( PubMed, DOI )

Mori, S.; Hirano T.; Takaguchi, A.; Fujiwara, T.; Okazaki, Y.; Kagechika, H.. Selective Reagent for Detection of N-ε-Monomethylation of a Peptide Lysine Residue through SNAr Reaction European Journal of Organic Chemistry. 2017.07; 3606-3611.

Yoshizaki, Y.; Mori, T.; Ishigami-Yuasa, M.; Kikuchi, E.; Takahashi, D.; Zeniya, M.; Nomura, N.; Mori, Y.; Araki, Y.; Ando, F.; Mandai, S.; Kasagi, Y.; Arai, Y.; Sasaki, E.; Yoshida, S.; Kagechika, H.; Rai, T.; Uchida, S.; Sohara, E.. Drug-Repositioning Screening for Keap1-Nrf2 Binding Inhibitors using Fluorescence Correlation Spectroscopy Science Reports. 2017.07; 7 3945.

Yoshioka, H.; Yamada, A.; Nishiyama, Y.; Kagechika, H.; Hashimoto, Y.; Fujii, S.. Development of nonsteroidal glucocorticoid receptor modulators based on N-benzyl-N-(4-phenoxyphenyl)benzenesulfonamide scaffold Bioorganic and Medicinal Chemistry. 2017.07; 25 (13): 3461-3470.

Ishigami-Yuasa M, Watanabe Y, Mori T, Masuno H, Fujii S, Kikuchi E, Uchida S, Kagechika H. Development of WNK signaling inhibitors as a new class of antihypertensive drugs. Bioorganic & medicinal chemistry. 2017.07; 25 (14): 3845-3852. ( PubMed, DOI )

Ishigami-Yuasa, M.; Watanabe, Y.; Mori, T.; Masuno, H.; Fujii, S.; Kikuchi, E.; Uchida, S.; Kagechika, H.. Development of WNK signaling inhibitors as a new class of antihypertensive drugs Bioorganic and Medicinal Chemistry. 2017.06; 25 (14): 3845-3852.

Nguyen, B. N.; Okuno, Y.; Ajiro, M.; Iida, K.; Denawa, M.; Yamamoto, M.; Sakamoto, N.; Kagechika, H.; Hagiwara, M.. Retinoid derivative Tp80 exhibits anti-hepatitis C virus activity through restoration of GI-GPx expression Journal of Medical Virology. 2017.05; 89 (7): 1224-1234.

Hoang, H. N.; Nagashima, Y.; Mori, S.; Kagechika, H.; Matsuda, T.. CO2-expanded bio-based liquids as novel solvents for enantioselective biocatalysis Tetrahedron . 2017.05; 73 (20): 2984-2989.

Perri, M.; Caroleo, Nannan M. C.; Gallelli, L. L.; De Sarro, G.; Kagechika, H.; Cione, E.. 9-cis Retinoic acid modulates myotrophin expression and its miR in physiological and pathophysiological cell models Experimental Cell Research. 2017.04; 354 25-30.

Tsuji, M.; Shudo, K.; Kagechika, H.. The receptor subtype selectivity of retinoid X and retinoic acid re-ceptors via quantum mechanics FEBS Open Bio. 2017.03; 7 391-396.

Oya, Y.; Mondal, A.; Rawangkan, A.; Umsumarng, S.; Iida, K.; Watanabe, T.; Kanno, M.; Suzuki, K.; Li, Z.; Kagechika, H.; Shudo, K.; Fujiki, H.; Suganuma, M.. Down-regulation of histone deacetylase 4, −5 and −6 as a mechanism of synergistic enhancement of apoptosis in human lung cancer cells treated with the combination of a synthetic retinoid, Am80 and green tea catechin Journol of Nutritional Biochemistry. 2017.01; 42 7-16.

Okamoto-Uchida, Y.; Yu, R.; Miyamura, N.; Arima, N.; Ishigami-Yuasa, M.; Kagechika, H.; Yoshida, S.; Hosoya, T.; Nawa, M.; Kasama, T.; Asaoka, Y.; Alois, R. W.; Elling, U.; Penninger, J. M.; Nishina, S.; Azuma, N.; Nishina, H.. The mevalonate pathway regulates primitive streak formation via protein farnesylation Science Reports. 2016.10; 6 37697.

Kinoshita, M.; Negishi, M.; Sakai, H.; Hirano, T.; Mori, S.; Fujii, S.; Kagechika, H.; Tanatani, A.. Development of 6-Arylcoumarins as Nonsteroidal Progesterone Antagonists. Structure-activity Relationships and Fluorescence Properties Bioorganic & Medicinal Chemistry. 2016.09; 24 (21): 5602-5610.

Yamada, A.; Kazui, Y.; Yoshioka, H.; Tanatani, A.; Mori, S.; Kagechika, H.; Fujii, S. . Development of N-(4-Phenoxyphenyl)benzenesulfonamide Derivatives as Novel Nonsteroidal Progesterone Receptor Antagonists ACS Medicinal Chemistry Letters. 2016.09; 7 (12): 1028-1033.

Yokoo, H.; Ohsaki, A.; Kagechika, H.; Hirano T.. Structural development of canthin-5,6-dione moiety as a fluorescent dye and its application to novel fluorescent sensors Tetrahedron . 2016.08; 72 5872-5879.

Fujiwara, T.; Ohira, K.; Urushibara, K.; Ito, A.; Yoshida, M.; Kanai, M.; Tanatani, A.; Kagechika, H.; Hirano, T.. Steric structure–activity relationship of cyproheptadine derivatives as inhibitors of histone methyltransferase Set7/9 Bioorganic & Medicinal Chemistry. 2016.07; 24 4318-4323.

Hirano, T.; Noji, Y.; Shiraishi, T.; Ishigami-Yuasa, M.; Kagechika, H.. Development of an “OFF-ON-OFF” fluorescent pH sensor suitable for the study of intracellular pH Tetrahedron . 2016.06; 72 4925-4930.

Nagashima, S.; Maruyama, J.; Kawano, S.; Iwasa, H.; Nakagawa, K.; Ishigami-Yuasa, M.; Kagechika, H.; Nishina, H.; Hata, Y.. Validation of the chemical compound library screening for TAZ inhibitors by use of green fluorescence protein-fused TAZ Cancer Science. 2016.06; 107 (6): 791-802.

Takemoto, Y.; Ito, A.; Niwa, H.; Okamura, M.; Fujiwara, T.; Hirano, T.; Handa, N.; Umehara, T.; Sonoda, T.; Ogawa, K.; Tariq, M.; Nishino, N.; Dan, S.; Kagechika, H.; Yamori, T.; Yokoyama, S.; Yoshida, M.. Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription Journol of Medicinal Chemistry. 2016.04; 59 (8): 3650-3660.

Persaud, S. D.; Park, S. W.; Ishigami-Yuasa, M.; Koyano-Nakagawa, N.;, Kagechika, H.; Wei, L.-N.. All trans-retinoic acid analogs promote cancer cell apoptosis through non-genomic Crabp1 mediating ERK1/2 phosphorylation Science Reports. 2016.03; 6 22396.

Tsukada, H.; Kawabe, H.; Ohtaka, A.; Saito, Y.: Okamoto, Y.: Tori, M.; Kagechika, H.; Hirota, H.; Gong, X.; Kuroda, C.; Ohsaki, A.. Two new diterpenoids from Salvia przewarskii Natural Product Communications. 2016.01; 11 (2): 159-161.

Shrestha, R.; Tatsukawa, H.; Shrestha, R.; Ishibashi, N.; Matsuura, T.; Kagechika, H.; Kose, S.; Hitomi, K.; Imamoto, N.; Kojima, S.. Molecular mechanism by which acyclic retinoid induces nuclear localization of transglutaminase 2 in human hepatocellular carcinoma cells. Cell Death & Disease. 2015.12; 6 e2002. ( DOI )

Yu. R.: Miyamura, N.; Okamoto-Uchida, Y.; Arima, N.; Ishigami-Yuasa, M.; Kagechika, H.; Nishina, H.. A Modified Murine Embryonic Stem Cell Test for Evaluating the Teratogenic Effects of Drugs on Early Embryogenesis Plos ONE. 2015.11; 10 e0145286. ( DOI )

Saito-Hakoda, A.; Uruno, A.; Yokoyama, A.; Shimizu, K.; Parvin, R.; Kudo, M.; Saito-Ito, T.; Sato, I.; Kogure, N.; Suzuki, D.; Shimada, H.; Yoshikawa, T .; Fujiwara, I.; Kagechika, H.; Iwasaki, Y.; Kure, S.; Ito, S.; Sugawara, A.. Effects of RXR Agonists on Cell Proliferation/Apoptosis and ACTH Secretion/Pomc Expression Plos ONE. 2015.11; 10 e0141960. ( DOI )

Fujii, S.; Shimizu, A.; Takeda, N.; Oguchi, K.; Katsurai, T.; Shirakawa, H.; Komai, M.; Kagechika, H.. Systematic synthesis and anti-inflammatory activity of ω-carboxylated menaquinone derivatives - Investigations on identified and putative vitamin K2 metabolites - Bioorganic Medicinal Chemistry. 2015; 23 2344-2352.

Nishiyama, S.; Urushibara, K.; Masu, H.; Azumaya, I.; Kagechika, H. Tanatani, A.. Conformational and chiral properties of cyclic-tri(N-methyl-meta-benzamide) bearing amidino groups Chirality. 2015; 27 487-491. ( DOI )

Qin, X.-Y.; Fujii, S.; Shimizu, A.; Kagechika, H.; KOJIMA, S.. Carboxylic derivatives of vitamin K2 inhibit hepatocellular carcinoma cell growth through caspase/transglutaminase-related signaling pathways Journal of Nutritional Science and Vitaminology. 2015; 61 285-290.

Brun, P.-J., Grijalva, A., Rausch, R., Watson, E., Yuen, J. J., Das, B. C., Shudo, K., Kagechika, H., Leibel, R. L., Blaner, W. S.. Retinoic acid receptor signaling is required to maintain glucose-stimulated insulin secretion and β-cell mass FASEB Journal. 2015; 26 671-683. ( DOI )

11) Kikuchi, E.; Mori, T.; Zeniya, M.; Isobe, K.; Ishigami-Yuasa, M.; Fujii, S.; Kagechika, H.; Ishihara, T.; Mizushima, T.; Sasaki, S.; Sohara, E.; Rai, T.; Uchida, S.. Discovery of Novel SPAK Inhibitors That Block WNK Kinase Signaling to Cation Chloride Transporters. Journal of the American Society of Nephrology. 2015; 26 (7): 1525-1536. ( DOI )

Mori, S., Takeuchi, Y., Tanatani, A., Kagechika, H., Fujii, S.. Development of 1,3-diphenyladamantane derivatives as nonsteroidal progesterone receptor antagonists Bioorganic Medicinal Chemistry. 2015; 23 803-809. ( DOI )

Kawano, S.; Maruyama, J.; Nagashima, S.; Inami, K.; Qiu, W.; Iwasa, H.; Nakagawa, K.; Ishigami-Yuasa, M.; Kagechika, H.; Nishina, H.; Hata, Y.. A cell-based screening for TAZ activators identifies ethacridine, a widely used antiseptic and abortifacient, as a compound that promotes dephosphorylation of TAZ and inhibits adipogenesis in C3H10T1/2 cells The Journal of Biochemistry. 2015; 158 413-420. ( DOI )

Shiraishi, T.; Kagechika, H.; Hirano, T.. 6-Arylcoumarins: versatile scaffolds for fluorescent sensors New Journal of Chemistry. 2015; 39 8389-8396. ( DOI )

Tsuji, M.; Shudo, K.; Kagechika, H.. Docking simulations suggest that all-trans retinoic acid could bind to retinoid X receptors Journal of Computer Aided Molecular Design. 2015; 29 975-988. ( DOI )

Kodaka, M.; Yang, Z.; Nakagawa, K.; Maruyama, J.; Xu, X.; Sarkar, A.; Ichimura, A.; Nasu, Y.; Ozawa, T.; Iwasa, H.; Ishigami-Yuasa, M.; Ito, S.; Kagechika, H.; Hata, Y.. A new cell-based assay to evaluate myogenesis in mouse myoblast C2C12 cells Experimental Cell Research. 2015; 336 171-181. ( DOI )

Inoue, K.; Urushibara, K.; Kanai, M.; Yura, K.; Fujii, S.; Ishigami-Yuasa, M.; Hashimoto, Y.; Mori, S.; Kawachi, E.; Matsumura, M.; Hirano, T.; Kagechik, H.; Tanatani, A.. Design and synthesis of 4-benzyl-1-(2H)-phthalazinone derivatives as novel androgen receptor antagonists European Journal of Medicinal Chemistry. 2015; 102 310-319. ( DOI )

Ma, F.; Liu, S.-Y.; Razani, B.; Arora, N.; Li, B.; Kagechika, H.; Tontonoz, P.; Nunez, V.; Ricote, M.; Cheng, G.. Retinoid X receptor a attenuates host antiviral response by suppressing type I interferon Nature Communication. 2014; 5 5494. ( DOI )

Yang, Z. Y.; Nakagawa, K.; Sarkar, A.; Maruyama, J.; Iwasa, H.; Bao, Y. J.; Ishigami-Yuasa, M.; Ito, S.; Kagechika, H.; Hata, S.; Nishina, H.; Abe, S.; Kitagawa, M.; Hata, Y.. Screening with a Novel Cell-Based Assay for TAZ Activators Identifies a Compound That Enhances Myogenesis in C2C12 Cells and Facilitates Muscle Repair in a Muscle Injury Model Molecular Cellular Biology. 2014; 34 1607-1621.

Shiraishi, T.; Saito, T.; Kagechika, H.; Hirano, T.. Development of a novel fluorescent sensor to detect a specific range of pH Tetrahedron Letters. 2014; 55 6784-6786. ( DOI )

Fujii, S.; Kano, A.; Songkram, C.; Masuno, H.; Taoda, Y.; Kawachi, E.; Hirano, T.; Tanatani, A.; Kagechika, H.. Synthesis and structure-activity relationship of p-carborane-based non-secosteroidal vitamin D analogs. Bioorganic Medicinal Chemistry. 2014; 22 1227-1235. ( DOI )

Uruno, A.; Saito-Hakoda, A.; Yokoyama, A.; Kogure, N.; Matsuda, K.; Parvin, R.; Shimizu, K.; Sato, I.; Kudo, M.; Yoshikawa, T.; Kagechika, H.; Iwasaki, Y.; Ito, S.; Sugawara, A.. Retinoic acid receptor-α up-regulates proopiomelanocortin gene expression in AtT20 corticotroph cells. Endocrine Journol. 2014; 61 1105-1114. ( DOI )

Fujii, S.; Kobayashi, T.; Nakatsu, A.; Miyazawa, H.; Kagechika, H.. Synthesis and Structure–Activity Relationship Study of Triazine-Based Inhibitors of the DNA Binding of NF-κB Chemical Pharmaceutical Bulletin. 2014; 62 700-708. ( DOI )

Mori, S.; Takagaki, R.; Fujii, S.; Matsumura, M.; Tanatani, A.; Kagechika, H.. Lipase-catalyzed asymmetric acylation of boron cluster-containing secondary alcohols Tetrahedron Asymmetry. 2014; 25 1505-1512. ( DOI )

Canavan, M.; McCarthy, C.; Ben Larbi, N.; Dowling, J. K.; Collins, L.; O'Sullivan, F.; Hurley, G.; Murphy, C.; Quinlan, A.; Moloney, G.; Darby, T.; MacSharry, J.; Kagechika, H.; Moynagh, P.; Melgar, S.; Loscher, C. E.. Activation of liver X receptor suppresses the production of the IL-12 family of cytokines by blocking nuclear translocation of NF-kappa Bp50 Innate Immunology. 2014; 20 675-687. ( DOI )

Fujii, S.; Sekine, R.; Kano, A.; Masuno, H.; Songkram, C.; Kawachi, E.; Hirano, T.; Tanatani, A.; Kagechika, H.. Structural development of p-carborane-based potent non-secosteroidal vitamin D analogs Bioorganic Medicinal Chemistry. 2014; 22 5891-5901. ( DOI )

Fujii, S.; Nakano, E.; Yanagid, N.; Mori, S.; Masuno, H.; Kagechika, H.. Development of p-carborane-based nonsteroidal progesterone receptor antagonists Bioorganic Medicinal Chemistry. 2014; 22 5329-5337. ( DOI )

Fujii, S.; Kano, A.; Masuno, H.; Songkram, C.; Kawachi, E.; Hirano, T.; Tanatani, A.; Kagechika, H.. Design and synthesis of tetraol derivatives of　 1,12-dicarba-closo-dodecaborane as non-secosteroidal vitamin D analogs Bioorganic Medicinal Chemistry Letters. 2014; 24 4515-4519. ( DOI )

Fujii, S.; Yamada, A.; Nakano, E.; Takeuchi, Y.; Mori, S.; Masuno, H.; Kagechika, H.. Design and synthesis of nonsteroidal progesterone receptor antagonists based on C,C’-diphenylcarborane scaffold as a hydrophobic pharmacophore Europian Journol of Medicinal Chemistry. 2014; 84 264-277. ( DOI )

Takashi Murayama, Nagomi Kurebayashi, Ryosuke Ishida, Hiroyuki Kagechika. Reconstitution of depolarization-induced Ca2+ release platform for validation of skeletal muscle disease mutations and drug discovery. The 7th International Symposium on Biomedical Engineering 2022.11.25

Yoshihiro Tada, Shuto Kawasaki, Hiroyuki Kagechika, Shinya Fujii. Structure-property relationship and PR antagonistic activity of N-phenylphosphinamide derivatives. The 7th International Symposium on Biomedical Engineering 2022.11.25

Saki Hatsuzawa, Ryosuke Ishida, Hiroyuki Baba, Tadashi Hosoya, Hiroyuki Kagechika. Development of novel immunosuppressive compounds leading anti-inflammatory effect. The 7th International Symposium on Biomedical Engineering 2022.11.25

Xi Zeng, Ryosuke Ishida, Nagomi Kurebayashi, Murayama Takashi, Yuuga Yamamoto, Shuichi Mori, Hiroyuki Kagechika. Development of novel RyR2 selective inhibitor. The 7th International Symposium on Biomedical Engineering 2022.11.25

Shuichi Mori, Hiroto Iinuma, Takashi Murayama, Chin Xikun, Ryosuke Ishida, Nagomi Kurebayashi, Hiroyuki Kagechika. Structure development of ryanodine receptor 1(RyR1) inhibitor for activity and water-solubility. The 6th International Symposium on Biomedical Engineering (ISBE2021) 2021.12.02

Yoshihara S., Sasaki H., Kawasaki H., Yoshihara A., Masuno H., Kanda Y., Kagechika H, Tanatani A.. Structure-activity Relationship of Lithocholic Acid As Novel Nonsecosteroidal Vitamin D Derivatives. The 6th International Symposium on Biomedical Engineering (ISBE2021) 2021.12.02

Nao Namba, Yuichiro Matsumoto, Yuichi Hashimoto, Tomomi Noguchi-Yachide, Hiroyuki Kagechika, Shinya Fujii. Structure Development of Silicon-Containing Derivatives of T0901317 as Novel Liver X Receptor (LXR) Ligands. The 6th International Symposium on Biomedical Engineering (ISBE2021) 2021.12.02

Kotaro Ochiai, Hiroyuki Kagechika, Shinya Fujii. Design, Synthesis and Evaluation of Novel Androgen Receptor Ligand Bearing Ferrocene as the Hydrophobic Pharmacophore. The 6th International Symposium on Biomedical Engineering (ISBE2021) 2021.12.02

Kotaro Ochiai, Hiroyuki Kagechika, Shinya Fujii. Development of Androgen Receptor Ligands Bearing Ferrocene as the Hydrophobic Pharmacophore. AFMC International Medicinal Chemistry Symposium 2021 2021.11.29

Aya Tanatani, Chisaki Yoshioka, Hiroyuki Masuno, Nobutaka Numoto, Nobutoshi Ito, Hirata Naoya, Kanda Yasunari, Hiroyuki Kagechika. Development of Novel Lithocholic Acid Derivatives: Synthesis of Each Stereoisomer by Using Enzymatic Separation and The Vitamin D Activity. Symposium on Molecular Chirality 2021 2021.11.29 Hiroshima, Japan

Yoshihara S., Sasaki H., Kawasaki H., Yoshihara A., Masuno H., Kanda Y., Kagechika H, Tanatani A.. Structure-activity relationship of Lithocholic Acid as Novel Nonsecosteroidal Vitamin D Derivatives. AFMC International Medicinal Chemistry Symposium 2021 2021.11.29

Nao Namba, Yuichiro Matsumoto, Yuichi Hashimoto, Tomomi Noguchi-Yachide, Hiroyuki Kagechika, Shinya Fujii. Development of Subtype-Selective Liver X Receptor (LXR) Ligands Using Silicon Functionalities. AFMC International Medicinal Chemistry Symposium 2021 2021.11.29

Hiroyuki Kagechika. Development of Nuclear Receptor Ligands with Unique Pharmacophore. The 6th Joint Symposium between IBB/TMDU and Chulalongkorn University on Biomedical Materials and Engineering 2020.01.14

諸墨樹、森修一、影近弘之. カルボランを疎水性骨格として有する核内受容体LRH-1機能制御剤の創製. 日本薬学会第139年会 2019.03.20 東京

Hiroyuki Kagechika, Shinya Fujii, Tomoya Hirano, Shinya Mori, Aya Tanatani. Development of Functional Molecules Based on Unique Scaffolds. EPFL/TMDU/UTokyo Joint Symposium 2018 2018.09.19 Lausanne, Switzland

Tomoya Hirano, Chihiro Komatsu, Yuki Noji, Hiroyuki Kagechika. Development of photofunctional compounds that function under specific range of pH with “OFF-ON-OFF” type of change. Gordon Research Conference, Bioanalytical Sensors 2018.06.22 Newport, RI, USA

Soyoung Park, Junya Uchida, Ko Urushibara, Hiroyuki Kagechika, Takashi Kato, AyaTanatani. Self-assembly of Liquid-Crystalline Squaramides. 27th International Liquid Crystal Conference 2018.06.22 京都

Hidetomo Yokoo, Tomoya Hirano, Ayumi Ohsaki, Hiroyuki Kagechika. Development of novel environment-dependent fluorophore derived from fluorescent natural compounds. Gordon Research Conference, Bioanalytical Sensors 2018.06.22 Newport, RI, USA

Hiroyuki Kagehcika. Development of Novel Synthetic Retinoids with Unique Hydrophobic Pharmacophore. FASEB meeting on retinoid 2018.06.10 Steamboat Springs, Corolado, USA

Tomoya Hirano, Michitake Hirano, Takashi Fujiwara, Takashi Umehara, Akihiro Ito, Minoru Yoshida, Hiroyuki Kagechika. Structural development of cyproheptadine as an inhibitor for histone methyltransfearse Set7/9. Symposium on Frontier of Genomic Medicine ‘Retinoid (Am80, Tamibarotene) as therapeutics for intractable diseases’ 2018.01.29 東京

Haru Kawasaki, Harue Sasaki, Hiroyuki Masuno, Emiko Kawachi, Nobutoshi Ito, Hiroyuki Kagechika, Aya Tanatani. Development of Lithocholic Acid Derivatives with A 3-Hydroxyalky Group as Novel Nonsecosteroidal Vitamin D Analogs. Symposium on Frontier of Genomic Medicine ‘Retinoid (Am80, Tamibarotene) as therapeutics for intractable diseases’ 2018.01.29 東京

Mai Negishi, Hitomi Koga, Shuichi Mori, Hiroyuki Kagechika, Aya Tanatani. Development of Nitrogen-Containing Heteroaromatic Compounds as Novel Progesterone Antagonists. Symposium on Frontier of Genomic Medicine ‘Retinoid (Am80, Tamibarotene) as therapeutics for intractable diseases’ 2018.01.29 東京

Tsuyoshi Oikawa, Shinya Fujii, Hiroyuki Masuno, Emiko Kawachi, Hiroyuki Kagechika. Development of Novel Silyl-containing Retinoids. Symposium on Frontier of Genomic Medicine ‘Retinoid (Am80, Tamibarotene) as therapeutics for intractable diseases’ 2018.01.29 東京

Nozomi Tsuemoto, Shuichi Mori, Emiko Kawachi, Hiroyuki Kagechika. Development of novel retinoids bearing pentafluorosulfanyl group. Symposium on Frontier of Genomic Medicine ‘Retinoid (Am80, Tamibarotene) as therapeutics for intractable diseases’ 2018.01.29 東京

Yusuke Okazaki, Takashi Fujiwara, Asuka Takaguchi, Tomoya Hirano, Shuichi Mori, Hiroyuki Kagechika. Development of facile method to detect the activity of histone methyltransferase based on SNAr reaction. Symposium on Frontier of Genomic Medicine ‘Retinoid (Am80, Tamibarotene) as therapeutics for intractable diseases’ 2018.01.29 東京

Mari Ishigami-Yuasa, Yuko Watanabe, Honoka Suzuyama, Hiroyuki Masuno, Shinya Fujii, Takayasu Mori, Eriko Kikuchi, Shinichi Uchida, Hiroyuki Kagechika. Development of WNK Signaling Inhibitors as a New Class of Antihypertensive Drugs. Symposium on Frontier of Genomic Medicine ‘Retinoid (Am80, Tamibarotene) as therapeutics for intractable diseases’ 2018.01.29 東京

Shuichi Mori, Ryohei Takagaki, Shinya Fujii, Aya Tanatani, Hiroyuki Kagechika. Development of novel progesterone receptor ligands bearing m-carborane as a hydrophobic pharmacophore. Symposium on Frontier of Genomic Medicine ‘Retinoid (Am80, Tamibarotene) as therapeutics for intractable diseases’ 2018.01.29 東京

Aya Tanatani, Ko Urushibara, Mayumi Kudo, Shinya Fujii, Hyuma Masu, Isao Azumaya, Hiroyuki Kagechika. Helical Foldamers Based on the Conformational Properties of Aromatic Amides, Ureas and Squaramides. Chirality 2017/ISCD-29 2017.07.09 東京

Kagechika, H.. Development of Functional Molecules with Unique Scaffolds. The 3rd Joint Symp. IBB/TMDU & Chulalongkorn Univ. Biomed. Mater. Engineer. 2016.12.15 Bangkok

Rawangkan, A., Oya, Y., Iida, K., Kagechika, H., Shudo, K., Fujiki, H., Suganuma, M. . Innovative strategy of cancer treatment with the combination of Am80, a potent synthetic retinoid, and green tea catechin via down-regulation of　histone deacetylase 4, -5, and -6. Int. Symp. Biomed. Engineer. 2016.11.10 Tokyo

Ishigam-Yuasa, M., Ekimoto, H., Kagechika, H.. Synergistic inhibition of several human cancer cell proliferations by a synthetic retinoid tamibarotene (Am80) in combination with the epigenetic modulators. Int. Symp. Biomed. Engineer. 2016.11.10 Tokyo

Mori, S., Takagaki, R., Fujii, S., Matsumura, M., Tanatani, A., Kagechika, H.. Development of m-carborane-based progesterone receptor ligands and their optical resolution by lipase reaction. Int. Symp. Biomed. Engineer. 2016.11.10 Tokyo

Hirano, T., Noji, Y., Kato, D., Shiraishi, T., Kagechika, H.. Development of fluorescent sensors for microenvironemtal change. Int. Symp. Biomed. Engineer. 2016.11.10 Tokyo

Mori, S., Oshida, Y., Watanabe, Y., Yuasa, M., Kagechika, H.. Development of novel store-operated calcium entry inhibitors. Int. Chem. Biol. Symp 2016.10 Madison, USA

Okazaki, Y., Fujiwara, T., Takaguchi, A., Hirano, T., Mori, S., Kagechika, H.. Development of a facile method to detect the activity of histone methyltransferase based on SNAr reaction. Int. Chem. Biol. Symp 2016.10 Madison, USA

Tanatani, A., Tojo, Y., Urushibara, K., Yamamoto, S., Mori, H., Masu, H., Kudo, M., Hirano, T., Kagechika, H.. N-Alkylated Pyrroleamide Oligomers with Folded Cis-Amide Conformation. Symposium on Foldamers 2016 2016.09.26 Bordeaux-Pessac, France

Hirano, T., Shiraishi, T., Noji, Y., Kato, D., Kagechika, H.. Development of fluorescent sensors for microenvironmental change based on fluorescent compounds library. 252nd ACS National Meeting 2016.08 Philadelphia, USA

Yokoo, H., Hirano, T., Ohsaki, A., Kagechika, H.. Development of Novel Fluorescent Sensors Based on Fluorescent Natural Compounds. 252nd ACS National Meeting 2016.08 Philadelphia, USA

Kagehcika, H.. Development of novel retinoids with unique hydrophobic pharmacophore. FASEB meeting on retinoid 2016.06.20 Florida, USA

Hirano, T., Hirano, M., Fujiwara, T., Ohira, K., Ito, A., Yoshida, M., Kagechika, H. . Structure-activity relationships of cyroheptadine as inhibitors of histone methyltransferase, Set7/9. International symposium for RIKEN epigenetics program 2016.02 Tokyo

Mori, S., Okazaki, Y., Fujiwara, T., Takaguchi, A., Hirano, T., Kagechika, H.. Development of novel assay methods for detection of N-monomethylated lysine using SNAr reaction. International symposium for RIKEN epigenetics program, 2016.02 Tokyo

Shiraishi, T., Hirano, T., Noji, Y., Saito, T., Kagechika, H.. Development of various fluorescent sensors based on coumarin scaffold. Pacifichem 2015 2015.12.15 Hawaii, USA

Ainiwaer, D., Ito, S., Nakagawa, K., Zeyu, Y., Yuasa, M., Hata, Y., Kagechika, H.. Development of novel activators for transcriptional co-activator TAZ involved in Hippo pathway. Pacifichem 2015 2015.12.15 Hawaii, USA

Yuasa, M., Mori, T., Fujii, S., Watanabe, Y., Suzuyama, H., Kikuchi, E., Uchida, S., Kagechika, H.. Development of WNK signaling inhibitors as new class of antihypertensive drugs. Pacifichem 2015 2015.12.15 Hawaii, USA

Fukasawa, H., Shudo, K., Kagechika, H.. Therapeutic potential of tamibarotene for Alzheimer's disease and COPD. 3rd International conference on retinoid 2015.10.21 Gifu, Japan

Oya, Y., Suganuma, M., Iida, K., Sakai, R., Kagechika, H., Shudo, K., Fujiki, H. . Combination of EGCG and Am80 is an innovative cancer treatment mediated through induction of GADD153 and DR5 gene expressions caused by inhibition of histone deacetylase 4 and 5. 3rd International conference on retinoid 2015.10.21 Gifu, Japan

Hirano, M., Hirano, T., Fujiwara, T., Ohira, K., Kagechika, H., Ito, A., Yoshida, M.. Study for the development of inhibitors for Set7/9. 3rd International conference on retinoid 2015.10.21 Gifu, Japan

Mori, S., Takagaki, R., Fujii, S., Matsumura, M., Tanatani, A., Kagechika, H.. Development of m-carborane-based progesterone receptor ligands and their optical resolution by lipase-catalyzed reaction. 3rd International conference on retinoid 2015.10.21 Gifu, Japan

Ishigami-Yuasa, M., Ekimoto, H., Kagechika, H.. Synergistic inhibition of viable human cancer cells by a synthetic retinoid tamibarotene (Am80) in combination with DNA methyltransferase or histone deacetylase inhibitors. 3rd International conference on retinoid 2015.10.21 Gifu, Japan

Kagechika, H., Fujii, S., Shirakawa, H., Komai, M., Qin, X.-Y., Kojma, S.. Systematic synthesis and biological activities of ω-carboxylated menaquinone derivatives.. FASEB meeting on vitamin K 2015.06.12 Chicago, USA

Masuno, H., Fujii, S., Hirano, T.; Kawachi, E.; Tanatani, A.; Kagechika, H.. Development of carborane-based non-secosteroidal vitamin D analogs. 18th Workshop on Vitamin D 2015.04.21 Delft, Nederland

Tomoya Hirano, Takuya Shiraishi, Toshiki Saito, Hiroyuki Kagechika. Development of Fluorescent Sensors with its Functions Regulated by Chemical or Enzymatic Reaction. 3rd Intrnational Chemical Biology Meeting 2014.11 San Francisco, USA

Shuichi Mori, Ryohei Takagaki, Shinya Fujii, Mio Matsumura, Aya Tanatani, Hiroyuki Kagechika. Lipase-catalyzed optical resolution and biological activity of boron-cluster-based progesterone receptor ligands. 3rd Intrnational Chemical Biology Meeting 2014.11 San Francisco, USA

Hiroyuki Kagechika, Eiichi Nakano, Ayumi Yamada, Yuki Takeuchi, Shuichi Mori, Hiroyuki Masuno, Shinya Fujii. Design and Synthesis of C,C’-Diphenylcarborane Derivatives as Novel Progesterone Receptor Antagonists. IMEBoron XV 2014.08 Prague, Czech Republic

Shigeru Ito, Kentaro Nakagawa, Zeyu Yang, Mari Yuasa, Yutaka Hata, Hiroyuki Kagechika. Investigation of regulatory compounds toward transcriptional co-activator TAZ. EMBO Conference Series: Chemical Biology 2014 2014.08 Heidelberg, Germany

Shinya Fujii, Shotaro Iihama, Hiroyuki Kagechika. Synthesis and Characterization of Novel m-Ccarborane-Containing Porphyrinoid. IMEBoron XV 2014.08 Prague, Czech Republic

Hiroyuki Kagechika. Development of Novel Synthetic Retinoids with Unique Hydrophobic Core Structure. FASEB 2nd International retinoid meeting 2014.06.05 Chicago, USA

Mari Yuasa, Shuichi Mori, Yohei Watanabe, Hiroyuki Kagechika. Novel　Store-Operated Calcium Entry (SOCE) inhibitors having the retinoid-like structure. FASEB 2nd International retinoid meeting 2014.06.05 Chicago, USA

Ishigami-Yuasa, M., Ekimoto, H., Kagechika, H.. Synergistic inhibition of several human cancer cell proliferations by a synthetic retinoid tamibarotene (Am80) in combination with the epigenetic modulators. FASEB meeting on retinoid Florida, USA

Tsuemoto, N., Mori, S., Kawachi, E., Kagechika, H.. Design and synthesis of novel RAR ligands containing pentafluorosulfanyl group. FASEB meeting on retinoid Florida, USA